Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-017968
Filing Date
2016-05-05
Accepted
2016-05-05 16:06:37
Documents
61
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20160331.htm 10-Q 1471913
2 EX-31.1 akba-ex311_6.htm EX-31.1 17264
3 EX-31.2 akba-ex312_7.htm EX-31.2 17280
4 EX-32.1 akba-ex321_8.htm EX-32.1 11875
5 EX-99.1 akba-ex991_9.htm EX-99.1 82467
6 GRAPHIC gen21ym2tkji000001.jpg GRAPHIC 2066
  Complete submission text file 0001564590-16-017968.txt   6141091

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT akba-20160331.xml EX-101.INS 1400840
8 XBRL TAXONOMY EXTENSION SCHEMA akba-20160331.xsd EX-101.SCH 42776
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20160331_cal.xml EX-101.CAL 47422
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20160331_def.xml EX-101.DEF 142516
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20160331_lab.xml EX-101.LAB 324644
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20160331_pre.xml EX-101.PRE 260496
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 161623685
SIC: 2834 Pharmaceutical Preparations